These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22542316)

  • 61. Evolution of fit-for-purpose biomarker validations: an LBA perspective.
    Neely RJ
    Bioanalysis; 2018 Jun; 10(12):905-907. PubMed ID: 29923756
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
    Beckman RA; Chen C
    Adv Exp Med Biol; 2015; 867():81-90. PubMed ID: 26530361
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.
    Khoury JD; Wang WL; Prieto VG; Medeiros LJ; Kalhor N; Hameed M; Broaddus R; Hamilton SR
    Clin Cancer Res; 2018 Feb; 24(3):521-531. PubMed ID: 28839110
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biomarkers in early-phase trials: fundamental issues.
    Yee LM; Lively TG; McShane LM
    Bioanalysis; 2018 Jun; 10(12):933-944. PubMed ID: 29923753
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.
    Lee JW; Weiner RS; Sailstad JM; Bowsher RR; Knuth DW; O'Brien PJ; Fourcroy JL; Dixit R; Pandite L; Pietrusko RG; Soares HD; Quarmby V; Vesterqvist OL; Potter DM; Witliff JL; Fritche HA; O'Leary T; Perlee L; Kadam S; Wagner JA
    Pharm Res; 2005 Apr; 22(4):499-511. PubMed ID: 15846456
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Planning clinically relevant biomarker validation studies using the "number needed to treat" concept.
    Day RS
    J Transl Med; 2016 May; 14(1):117. PubMed ID: 27146704
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Validation of new cancer biomarkers: a position statement from the European group on tumor markers.
    Duffy MJ; Sturgeon CM; Sölétormos G; Barak V; Molina R; Hayes DF; Diamandis EP; Bossuyt PM
    Clin Chem; 2015 Jun; 61(6):809-20. PubMed ID: 25882892
    [TBL] [Abstract][Full Text] [Related]  

  • 68. University of Pennsylvania 5th annual conference on statistical issues in clinical trials: emerging statistical issues in biomarker validation (Morning Session).
    DeMets D; Wittes J; Siegel J
    Clin Trials; 2013 Oct; 10(5):680-9. PubMed ID: 24130200
    [No Abstract]   [Full Text] [Related]  

  • 69. Adaptation of commercial biomarker kits and proposal for 'drug development kits' to support bioanalysis: call for action.
    Islam R; Kar S; Islam C; Farmen R
    Bioanalysis; 2018 Jun; 10(12):945-955. PubMed ID: 29939797
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.
    Sölétormos G; Duffy MJ; Hayes DF; Sturgeon CM; Barak V; Bossuyt PM; Diamandis EP; Gion M; Hyltoft-Petersen P; Lamerz RM; Nielsen DL; Sibley P; Tholander B; Tuxen MK; Bonfrer JM
    Clin Chem; 2013 Jan; 59(1):52-9. PubMed ID: 23034139
    [TBL] [Abstract][Full Text] [Related]  

  • 71. University of Pennsylvania 5th annual conference on statistical issues in clinical trials: emerging statistical issues in biomarker validation (afternoon session).
    Rubin E; LaVange L; DeGruttola V
    Clin Trials; 2013 Oct; 10(5):701-8. PubMed ID: 23988466
    [No Abstract]   [Full Text] [Related]  

  • 72. Applications of genetic technologies to cancer screening, prevention, diagnosis, prognosis, and treatment.
    Peters JA
    Semin Oncol Nurs; 1997 May; 13(2):74-81. PubMed ID: 9114474
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Design of clinical trials for biomarker research in oncology.
    Mandrekar SJ; Sargent DJ
    Clin Investig (Lond); 2011 Dec; 1(12):1629-1636. PubMed ID: 22389760
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Integrated Chemometrics and Statistics to Drive Successful Proteomics Biomarker Discovery.
    Suppers A; van Gool AJ; Wessels HJCT
    Proteomes; 2018 Apr; 6(2):. PubMed ID: 29701723
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evolution of proteomic biomarker for chronic liver disease: Promise into reality.
    Nallagangula KS; Shashidhar KN; Lakshmaiah V; Muninarayana
    J Circ Biomark; 2018; 7():1849454418777186. PubMed ID: 29854010
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Choosing biomarkers wisely.
    Cancer Discov; 2014 Aug; 4(8):861-2. PubMed ID: 25092727
    [No Abstract]   [Full Text] [Related]  

  • 77. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal.
    Hammond ME; Taube SE
    Semin Oncol; 2002 Jun; 29(3):213-21. PubMed ID: 12063674
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Parallelism: the foundation of biomarker assay development and validation.
    Mehta D; Purushothama S; Stevenson L
    Bioanalysis; 2018 Jun; 10(12):897-899. PubMed ID: 29923751
    [No Abstract]   [Full Text] [Related]  

  • 79. Making the cut: untangling clinical protein biomarker discovery and validation.
    Gold L; Williams S; Janjic N; Saccomano N; Steele F
    Biomark Med; 2011 Apr; 5(2):189-91. PubMed ID: 21473721
    [No Abstract]   [Full Text] [Related]  

  • 80. Challenges and Opportunities for Biomarker Validation.
    Hey SP; D'Andrea E; Jung EH; Tessema F; Luo J; Gyawali B; Kesselheim AS
    J Law Med Ethics; 2019 Sep; 47(3):357-361. PubMed ID: 31560620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.